ArticleTranslational neuroscience2018
Effect of Myricetin on Primary Open-angle Glaucoma.
Article in Translational neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Exploring myricetin: A comprehensive review of its pharmacological potential, formulation strategies, and clinical outlook.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- MoroccanInternational journal of food science · 2026Article
- Hyaluronic Acid-PEG-PLGA Nanoparticles Encapsulating Myricetin Attenuate NMDA-Induced Retinal Ganglion Cell Injury Associated with Microglia-Related Neuroinflammatory Responses.International journal of nanomedicine · 2026Article
- Unlocking the Pharmacological Potential of Myricetin Against Various Pathogenesis.International journal of molecular sciences · 2025Review
- Photoprotective Effects of Phytochemicals on Blue Light-Induced Retinal Damage: Current Evidence and Future Perspectives.Nutrients · 2025Review
- Candidate SNP Markers Significantly Altering the Affinity of the TATA-Binding Protein for the Promoters of Human Genes Associated with Primary Open-Angle Glaucoma.International journal of molecular sciences · 2024Article
- Role of Inflammation in Canine Primary Glaucoma.Animals : an open access journal from MDPI · 2023Review
- Next-generation nanomaterials: advancing ocular anti-inflammatory drug therapy.Journal of nanobiotechnology · 2023Review
- Novel Antioxidant Insights of Myricetin on the Performance of Broiler Chickens and Alleviating Experimental Infection withAntioxidants (Basel, Switzerland) · 2023Article
- Comparison of the Drug-Induced Efficacies between Omidenepag Isopropyl, an EP2 Agonist and PGF2α toward TGF-β2-Modulated Human Trabecular Meshwork (HTM) Cells.Journal of clinical medicine · 2022Article
- An Innovative In Vitro Open-Angle Glaucoma Model (IVOM) Shows Changes Induced by Increased Ocular Pressure and Oxidative Stress.International journal of molecular sciences · 2021Article
- Targeting the NLRP3 Inflammasome in Glaucoma.Biomolecules · 2021Review
- Ocular Delivery of Polyphenols: Meeting the Unmet Needs.Molecules (Basel, Switzerland) · 2021Review
- Can Polyphenols in Eye Drops Be Useful for Trabecular Protection from Oxidative Damage?Journal of clinical medicine · 2020Article
- New micelle myricetin formulation for ocular delivery: improved stability, solubility, and ocular anti-inflammatory treatment.Drug delivery · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary open angle glaucoma (POAG) is the most common form of glaucoma, with a multifactorial etiology that results in retinal ganglion cell death and loss of vision. In this study, we assessed the effects of myricetin on the trabecular meshwork cells in POAG.
methodsIn the
resultsPOAG TM cells exposed to myricetin (25, 50 or 100 μM) exhibited significantly lowered reactive oxidative species (ROS) levels and lipid peroxidation products. The expressions of transforming growth factors (TGFβ1/β2), vascular endothelial growth factor, and senescence markers (senescence associated-β-galactosidase, cyclin-dependent kinase inhibitors-p16 and p21) were substantially down-regulated in POAG TM cells exposed to myricetin. Myricetin effectively prevented IOP elevation in glaucoma-induced rats and decreased inflammatory cytokines (IL-1α, IL-1β, IL-6, Il-8, TNF-α) in the aqueous humor and POAG TM cells of glaucoma-induced rats.
conclusionThe observations of the study illustrate the protective effects of myricetin in glaucomatous TM cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.